NEW YORK (GenomeWeb News) – 23andMe today announced that it has started the process for regulatory clearance of its Personal Genome Service.

The Mountain View, Calif.-based consumer genetics testing firm said it has submitted its first round of 510(k) documentation to the US Food and Drug Administration, addressing concerns on the agency's part about tests such as those offered by 23andMe that are marketed directly to the public.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.